Chester County News and Community Website
PHILADELPHIA, PA & SAN FRANCISCO, CA & SHANGHAI, China — Dispatch Bio and CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK) said they have entered into a clinical collaboration to conduct …
Dispatch Bio and CARsgen Strike China Deal to Test New CAR T Approach Read More
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) said preliminary 12-month data from its Phase 2 ArMaDa clinical trial showed meaningful reductions in disease progression for patients with geographic atrophy, a …
Ocugen (NASDAQ: OCGN) Reports Strong Midstage Data for Gene Therapy Read More
PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) said detailed clinical data from early-stage studies of its long-acting hormone-suppressing drug Teverelix have been accepted for presentation at a major international …
Medicus Gene-Blocking Drug Shows Fast Hormone Control Ahead of Key Endocrine Meet Read More
WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) said it has launched a placebo-controlled Phase 1b proof-of-concept trial of ATI-052, an experimental bispecific antibody aimed at treating atopic dermatitis, marking …
Aclaris Pushes New Antibody Into Skin Disease Trial, Eyes Asthma Next Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) said newly published clinical trial data support the safety and early effectiveness of its experimental gene therapy for Stargardt disease, a rare inherited …
Gene Therapy Slows Vision Loss in Stargardt Trial, Fueling Hope for First Treatment Read More
WASHINGTON, D.C. — The U.S. Food and Drug Administration signaled a sweeping shift in how cutting-edge therapies reach patients this month, unveiling regulatory flexibility for cell and gene therapies, modernizing …
FDA Clears Faster Path for Gene Cures as Rare Disease Breakthrough Arrives Read More
WILMINGTON, DE — Incyte (Nasdaq: INCY) on Thursday unveiled breakthrough results from a pivotal late-stage cancer trial that could redefine first-line treatment for one of the most aggressive forms of …
New Incyte Drug Combo Shows Power Against Deadly Lymphoma Read More
SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) said its experimental immune therapy nipocalimab cleared a major clinical hurdle in systemic lupus erythematosus, delivering the first positive Phase 2b …
J&J’s Lupus Breakthrough Sets the Stage for a High-Stakes Phase 3 Push Read More
KING OF PRUSSIA, PA — SEED Therapeutics Inc. took a critical step from laboratory promise to human testing with the first patient dosed in a Phase 1a study of ST-01156, …
SEED’s First Human Dose Ignites a High-Stakes Bet on RNA-Targeted Cancer Drugs Read More
WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) is moving toward what could be a defining year, with a late-stage pipeline aimed at some of the most underserved rare skin …
Palvella’s QTORIN Pipeline Targets a Breakout Moment in Rare Skin Care Read More